Genelux (NASDAQ:GNLX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genelux (NASDAQ:GNLX) in a report published on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Genelux Stock Performance

Shares of GNLX stock opened at $2.70 on Monday. The firm has a market capitalization of $93.77 million, a P/E ratio of -2.84 and a beta of -1.41. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $6.50. The stock’s fifty day moving average is $4.06 and its two-hundred day moving average is $3.10.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). On average, equities analysts forecast that Genelux will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Genelux

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GNLX. XTX Topco Ltd acquired a new position in shares of Genelux in the 3rd quarter valued at $59,000. Geode Capital Management LLC raised its stake in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares during the period. Apollon Wealth Management LLC lifted its stake in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after purchasing an additional 2,857 shares in the last quarter. D.A. Davidson & CO. acquired a new position in Genelux during the 4th quarter worth about $51,000. Finally, LifeSteps Financial Inc. grew its position in Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after acquiring an additional 8,715 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.